# E-Health Now

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/e-health-now

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.huameihaolian.com
- Total disclosed funding: $14M
- Latest round: Series D (Mar 2, 2026)
- Investors on record: 15

## About

Established in 2017 and based in Beijing, China, Huamei Haolian Medical Technology (Beijing) Co., Ltd., trading under the name E-Health Now, operates as a medical company that focuses on providing telemedicine and medical services. It was recognized as the National High-tech Enterprise. The company has branch offices in Shanghai, Hainan, Yinchuan, and the United States, strategic cooperation agreements have been signed with nearly 60 domestic financial and insurance institutions and 7 international high-quality medical systems with more than 2,000 international experts in 41 specialties. In March 2026, the firm closed a series D funding co-led by Efung Capital, Shenzhen YHLO Biological Technology, Ventech China and Borchid Capital.

The company mainly provides holistic health service platforms. Its services include consultation with tertiary hospitals and overseas medical resource matching, medical screening, telemedicine, etc. Its products include an artificial intelligence digital medical and health service platform, Hua Doctor AI General Practitioner, Hua Doctor AI Precision Medical Treatment, etc. Hua Doctor's AI precision medical treatment has the functions of user symptom analysis, health problem consultation, and accurate triage.

The company generates revenue from providing its digital medical and health management platforms to enterprise and medical clients. 

The company plans to use the series D funding to accelerate the development of its AI Agent general healthcare system, collaborate with major hospitals to create specialized medical products, and advance the strategic upgrade of its digital ecosystem to achieve a fully integrated smart care model.

## Funding rounds

- Series D, Mar 2, 2026 — GSR Ventures, Ventech China, Efung Capital, Shitao Capital, Borchid Capital, Shenzhen YHLO Biological Technology, Dongfang State-owned Assets
- Series C, Sep 24, 2025 — CDH Investments, SIFT Capital Partners, Marathon Venture Partners, Jiupin Investment Management (Shanghai), Chunhui Fund
- Series C, Jul 13, 2024, $14M — Ameba Capital, Ventech China, Borchid Capital
- Series B, May 30, 2023 — GSR Ventures, Ventech China, Langrun Capital, Shitao Capital, Suzhou Wujiang Industrial Investment
- Series A, Aug 15, 2022 — Shitao Capital, Borchid Capital
- Series A, Jun 23, 2022 — GSR Ventures, Ventech China, Langrun Capital
- Series A, Apr 23, 2021 — Ventech China

## Investors

- Ventech China (https://capitalatlas.ai/funds/ventech-china) — Series A, Series B, Series C, Series D
- GSR Ventures (https://capitalatlas.ai/funds/gsr-ventures) — Series A, Series B, Series D
- Langrun Capital (https://capitalatlas.ai/funds/langrun-capital) — Series A, Series B
- Shitao Capital (https://capitalatlas.ai/funds/shitao-capital) — Series A, Series B, Series D
- Borchid Capital (https://capitalatlas.ai/funds/borchid-capital) — Series A, Series C, Series D
- Suzhou Wujiang Industrial Investment — Series B
- Ameba Capital (https://capitalatlas.ai/funds/ameba-capital) — Series C
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series C
- SIFT Capital Partners — Series C
- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Series C
- Jiupin Investment Management (Shanghai) — Series C
- Chunhui Fund — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- Shenzhen YHLO Biological Technology — Series D
- Dongfang State-owned Assets — Series D